The subsequent GATHER3 trial compensated for this disappointing result by including a secondary biopsy in the assessment, and of the 13 HER2-positive GC patients treated with T-DM1, three were negative for HER2 during treatment, and therefore, no disease remission was observed; the ORR of the remaining patients was 44% [69]. This evidence concerns the gene ERBB2 and gastric cancer.